Priya Handa, Bryan D. Maliken, James E. Nelson, Vicki Morgan‐Stevenson, Donald J. Messner, Barjinderjit K. Dhillon, Heather M. Klintworth, Mary Beauchamp, Matthew M. Yeh, Clinton T. Elfers, Christian L. Roth, Kris V. Kowdley – 21 November 2013 – Obesity and adiponectin depletion have been associated with the occurrence of nonalcoholic fatty liver disease (NAFLD). The goal of this study was to identify the relationship between weight gain, adiponectin signaling, and development of nonalcoholic steatohepatitis (NASH) in an obese, diabetic mouse model.

Benjamin Garlipp, Thierry Baere, Robert Damm, Romy Irmscher, Mark Buskirk, Patrick Stübs, Frederic Deschamps, Frank Meyer, Ricarda Seidensticker, Konrad Mohnike, Maciej Pech, Holger Amthauer, Hans Lippert, Jens Ricke, Max Seidensticker – 21 November 2013 – In patients with liver malignancies potentially amenable to curative extended right hepatectomy but insufficient size of the future liver remnant (FLR), portal vein embolization (PVE) of the tumor‐bearing liver is used to induce contralateral liver hypertrophy but leaves the tumor untreated.

Xin Yang, Xiao‐Fei Zhang, Xu Lu, Hu‐Liang Jia, Lei Liang, Qiong‐Zhu Dong, Qing‐Hai Ye, Lun‐Xiu Qin – 21 November 2013 – MicroRNA (miR)‐26a can suppress tumor growth and metastasis of hepatocellular carcinoma (HCC). Since angiogenesis is important for tumor growth and metastasis, we investigated the possible roles of miR‐26a in tumor angiogenesis. Down‐regulation of miR‐26a was found to correlate with an increased angiogenic potential of HCC.

Abbas Mourad, Sylvie Deuffic‐Burban, Nathalie Ganne‐Carrié, Thibaud Renaut‐Vantroys, Isabelle Rosa, Anne‐Marie Bouvier, Guy Launoy, Stephane Cattan, Alexandre Louvet, Sébastien Dharancy, Jean‐Claude Trinchet, Yazdan Yazdanpanah, Philippe Mathurin – 21 November 2013 – Because of the ongoing debate on the benefit of ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed the impact of screening on hepatitis C virus (HCV)‐related compensated cirrhosis patients aware of their HCV status.

Morris Sherman – 20 November 2013

Len Verbeke, Ricard Farre, Jonel Trebicka, Mina Komuta, Tania Roskams, Sabine Klein, Ingrid Vander Elst, Petra Windmolders, Tim Vanuytsel, Frederik Nevens, Wim Laleman – 20 November 2013 – The farnesoid X receptor (FXR) is a nuclear bile acid receptor involved in bile acid homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease.

Victoria L. Gadd, Richard Skoien, Elizabeth E. Powell, Kevin J. Fagan, Clay Winterford, Leigh Horsfall, Katharine Irvine, Andrew D. Clouston – 20 November 2013 – Although nonalcoholic fatty liver disease (NAFLD) is conventionally assessed histologically for lobular features of inflammation, development of portal fibrosis appears to be associated with disease progression. We investigated the composition of the portal inflammatory infiltrate and its relationship to the ductular reaction (DR), a second portal phenomenon implicated in fibrogenesis.

Joseph S. Dolina, Thomas J. Braciale, Young S. Hahn – 20 November 2013 – The liver is a tolerogenic environment exploited by persistent infections, such as hepatitis B (HBV) and C (HCV) viruses. In a murine model of intravenous hepatotropic adenovirus infection, liver‐primed antiviral CD8+ T cells fail to produce proinflammatory cytokines and do not display cytolytic activity characteristic of effector CD8+ T cells generated by infection at an extrahepatic, that is, subcutaneous, site.

John T. Skamarauskas, Fiona Oakley, Fiona E. Smith, Carlo Bawn, Michael Dunn, Daniel S. Vidler, Matthew Clemence, Peter G. Blain, Roy Taylor, Michael P. Gamcsik, Peter E. Thelwall – 16 November 2013 – Oxidative stress (OS) plays a central role in the progression of liver disease and in damage to liver by toxic xenobiotics. We have developed methods for noninvasive assessment of hepatic OS defenses by measuring flux through the glutathione (GSH) synthesis pathway. 13C‐labeled GSH is endogenously produced and detected by in vivo magnetic resonance after administration of [2‐13C]‐glycine.

Yusuf Gunay, Necdet Guler, Murat Dayangac, Fatih Taskesen, Onur Yaprak, Ertan Emek, Murat Akyildiz, Gulum Altaca, Yildiray Yuzer, Yaman Tokat – 15 November 2013 – Living donor liver transplantation (LDLT) is an accepted option for end‐stage liver disease, particularly in countries in which there are organ shortages. However, little is known about LDLT for obese patients. We sought to determine the effects of obesity on pretransplant living donor selection for obese recipients and their outcomes.